129 related articles for article (PubMed ID: 8456595)
1. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
Rozzini R; Zanetti O; Bianchetti A
Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
Rozzini R; Zanetti O; Bianchetti A
Acta Neurol (Napoli); 1992 Apr; 14(2):117-26. PubMed ID: 1414555
[TBL] [Abstract][Full Text] [Related]
3. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.
Moglia A; Sinforiani E; Zandrini C; Gualtieri S; Corsico R; Arrigo A
Clin Neuropharmacol; 1986; 9 Suppl 3():S73-8. PubMed ID: 3594459
[TBL] [Abstract][Full Text] [Related]
4. Clinical and neuropsychological study with oxiracetam versus placebo in patients with mild to moderate dementia.
Villardita C; Parini J; Grioli S; Quattropani M; Lomeo C; Scapagnini U
J Neural Transm Suppl; 1987; 24():293-8. PubMed ID: 3479527
[TBL] [Abstract][Full Text] [Related]
5. Benefits of rivastigmine on attention in dementia associated with Parkinson disease.
Wesnes KA; McKeith I; Edgar C; Emre M; Lane R
Neurology; 2005 Nov; 65(10):1654-6. PubMed ID: 16301500
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree.
Villardita C; Grioli S; Lomeo C; Cattaneo C; Parini J
Neuropsychobiology; 1992; 25(1):24-8. PubMed ID: 1603291
[TBL] [Abstract][Full Text] [Related]
7. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
Gallai V; Mazzotta G; Del Gatto F; Montesi S; Mazzetti A; Dominici P; Della Monica A
Acta Neurol (Napoli); 1991 Feb; 13(1):1-12. PubMed ID: 1867125
[TBL] [Abstract][Full Text] [Related]
8. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
Tariska P; Paksy A
Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
[TBL] [Abstract][Full Text] [Related]
9. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy.
Hessen E; Lossius MI; Reinvang I; Gjerstad L
Epilepsia; 2006 Dec; 47(12):2038-45. PubMed ID: 17201701
[TBL] [Abstract][Full Text] [Related]
10. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.
Doody RS; Ferris SH; Salloway S; Sun Y; Goldman R; Watkins WE; Xu Y; Murthy AK
Neurology; 2009 May; 72(18):1555-61. PubMed ID: 19176895
[TBL] [Abstract][Full Text] [Related]
11. CNS pharmacology and clinical therapeutic effects of oxiracetam.
Itil TM; Menon GN; Songar A; Itil KZ
Clin Neuropharmacol; 1986; 9 Suppl 3():S70-2. PubMed ID: 3594458
[TBL] [Abstract][Full Text] [Related]
12. Galantamine treatment of vascular dementia: a randomized trial.
Auchus AP; Brashear HR; Salloway S; Korczyn AD; De Deyn PP; Gassmann-Mayer C;
Neurology; 2007 Jul; 69(5):448-58. PubMed ID: 17664404
[TBL] [Abstract][Full Text] [Related]
13. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
Dysken MW; Katz R; Stallone F; Kuskowski M
J Neuropsychiatry Clin Neurosci; 1989; 1(3):249-52. PubMed ID: 2521069
[TBL] [Abstract][Full Text] [Related]
14. Selegiline versus oxiracetam in patients with Alzheimer-type dementia.
Falsaperla A; Monici Preti PA; Oliani C
Clin Ther; 1990; 12(5):376-84. PubMed ID: 2125242
[TBL] [Abstract][Full Text] [Related]
15. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
16. Oxiracetam in dementia: a double-blind, placebo-controlled study.
Bottini G; Vallar G; Cappa S; Monza GC; Scarpini E; Baron P; Cheldi A; Scarlato G
Acta Neurol Scand; 1992 Sep; 86(3):237-41. PubMed ID: 1414239
[TBL] [Abstract][Full Text] [Related]
17. Double-blind, randomized, placebo-controlled pilot study with anapsos in senile dementia: effects on cognition, brain bioelectrical activity and cerebral hemodynamics.
Alvarez XA; Pichel V; Pérez P; Laredo M; Corzo D; Zas R; Fernández-Novoa L; Sempere JM; Díaz J; Cacabelos R
Methods Find Exp Clin Pharmacol; 2000 Sep; 22(7):585-94. PubMed ID: 11196347
[TBL] [Abstract][Full Text] [Related]
18. Treatment trial of oxiracetam in Alzheimer's disease.
Green RC; Goldstein FC; Auchus AP; Presley R; Clark WS; Van Tuyl L; Green J; Hersch SM; Karp HR
Arch Neurol; 1992 Nov; 49(11):1135-6. PubMed ID: 1444879
[TBL] [Abstract][Full Text] [Related]
19. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
[TBL] [Abstract][Full Text] [Related]
20. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
